163 related articles for article (PubMed ID: 37253929)
1. Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
Wang Z; Yang Z; Qu C; Li J; Wang X
Int Urol Nephrol; 2023 Aug; 55(8):1957-1970. PubMed ID: 37253929
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
5. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism.
Kim H; Sin JI
Hum Vaccin Immunother; 2012 Nov; 8(11):1714-21. PubMed ID: 23151450
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
7. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Ramakrishnan S; Granger V; Rak M; Hu Q; Attwood K; Aquila L; Krishnan N; Osiecki R; Azabdaftari G; Guru K; Chatta G; Gueron G; McNally L; Ohm J; Wang J; Woloszynska A
Cell Death Differ; 2019 Oct; 26(10):2100-2114. PubMed ID: 30692641
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.
Park HR; Ju EJ; Jo SK; Jung U; Kim SH; Yee ST
BMC Cancer; 2009 Mar; 9():85. PubMed ID: 19292900
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model.
Xin M; Lin D; Yan N; Li H; Li J; Huang Z
Anticancer Drugs; 2022 Feb; 33(2):117-123. PubMed ID: 34561996
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
Yue T; Zheng X; Dou Y; Zheng X; Sun R; Tian Z; Wei H
BMC Cancer; 2016 Aug; 16(1):665. PubMed ID: 27549240
[TBL] [Abstract][Full Text] [Related]
13. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
14. A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.
Sun Y; Sedgwick AJ; Khan MA; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():724107. PubMed ID: 34858395
[TBL] [Abstract][Full Text] [Related]
15. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
18. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
19. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
He S; Yin T; Li D; Gao X; Wan Y; Ma X; Ye T; Guo F; Sun J; Lin Z; Wang Y
J Transl Med; 2013 Aug; 11():186. PubMed ID: 23937717
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
